Covid-19 briefing

Download GlobalData’s Covid-19 Executive Briefing report

- ECONOMIC IMPACT -

Latest update: 16 June

The global economy is forecasted to return to pre-crisis levels by the end of 2021 or early 2022.

The unemployment rate in OECD nations stood at 6.5% in March 2021, down from 6.6% in Feb 2021.

0.8%

According to the OECD, real GDP in the G20 area grew by 0.8% in Q1 2021 when compared to the last quarter and reached pre-pandemic level.

5.8%

The OECD revised its growth forecast for the world economy to 5.8% from its earlier projection of 4.2% in December 2020.

Impact of Covid-19 on equity indices

- SECTOR IMPACT: PHARMA -

Latest update: 15 June

industry development

Results from a recent GlobalData B2B survey indicate that Covid-19 has accelerated digital transformation efforts in Pharma by more than five years.

85%

At its present rate of vaccination, the US will be able to administer two doses of any vaccine to 85% of adults within 138 days.

Vaccine rollout

China has administered the most single doses of Covid-19 vaccines worldwide (892.77 million), followed by the US (309.32 million) and India (249.43 million). However, the US has lost its position in the top ten countries globally in the vaccination rate per 1,000 population.

Gibraltar has administered the most single doses of Covid-19 vaccine per 1,000 population worldwide, followed by Seychelles and the United Arab Emirates.

Gibraltar has the unusual distinction of vaccinating over 100% of its population, most likely because it is administering doses to individuals who are travelling to Gibraltar for vacation or for work but are not technically counted as residents.

Key pharma market developments

Clinical trials

The number of trials in the US and India has been growing at a much higher rate than in other countries.

With multiple vaccines having shown impressive efficacy, notably for reductions in the need for hospitalisation and mortality, the window for utility for Covid-19 therapies may be rapidly contracting.

With the Covid-19 pipeline becoming more crowded, developers may be forced to cut losses and terminate Covid-19 programmes if they do not appear promising.

However, this may be offset by increased illness caused by the rise of vaccine-resistant variants and shortages of vaccines in certain countries, such as India.

Vaccine hesitancy

Importantly, a significant percentage of adults in the US remain hesitant to receive a Covid-19 vaccine, with some surveys indicating that up to 30% of US adults would “probably” or “never” receive a Covid-19 vaccine.

This trend may dampen the benefit of the overall vaccine rollout and may make the herd immunity target of 70% difficult to achieve.

02/24/2024 07:38:57